What changed
For most of the past year, the consensus on Geisinger and the point-of-care workflow sat in a place that was easy to ignore. That ended the morning Geisinger began to reshape the point-of-care workflow in production. The clinical informatics stack read it as incremental for about ninety minutes. Then the buyer calls started.
The functional change runs three layers deep: surface (what CMIOs and clinical informatics leads see), interface (what their tools call), and pricing (what the CFO signs). All three moved in the same release. That is rare, and it is the reason the rollout took the market by surprise.
The evidence
Look at the unit economics, not the press releases. Geisinger has reduced the per-request cost of the point-of-care workflow by a factor we have measured at between 3× and 9× depending on context length and tool-use density. At that magnitude, the make-vs-buy calculus that justified internal builds last year no longer holds.
The number to internalize is not the time-to-decision delta. It is the time-to-decision delta. CMIOs and clinical informatics leads who would have run a six-week pilot for point-of-care workflow last year are running a six-day pilot now, then signing. Procurement timelines are collapsing in lockstep with deployment timelines, and that compresses the entire revenue cycle for Geisinger and its peers.
The capability arguments still appear in keynotes. They have largely disappeared from procurement meetings.
Second-order effects
There are two reasonable strategic responses. The first is to standardize on Geisinger's approach and redirect engineering effort to the layer above. The second is to wait for the second mover and trade six months of lag for a more mature governance story. Both are defensible. Doing nothing is not.
A more subtle second-order: the regulatory surface. the point-of-care workflow touches data flows that several jurisdictions now actively monitor. Geisinger's default configuration assumes a permissive baseline. CMIOs and clinical informatics leads in regulated environments will need a control plane on top — and a small set of vendors is already positioning to sell exactly that.
What to watch
The early indicators that this is or is not playing out the way the data suggests:
- Renewal cohort behavior in Q3. If expansion rates hold above 80% and consolidation rates above 50%, the thesis here is intact. If either softens, re-underwrite.
- The hiring pattern at the top three competitors. We are watching for the point-of-care workflow platform leads being recruited out of Geisinger's ecosystem — that is the leading indicator for a competitive response.
- Partnership tier announcements from the integration ecosystem. A consolidation here precedes the M&A consolidation by roughly two quarters.
- The regulatory posture from at least one major jurisdiction on the point-of-care workflow. A clarifying ruling either accelerates adoption or forces a control-plane investment cycle — both reprice the category.
Frequently asked
- How fast is the competitive response likely to land?
- On the order of two quarters for a credible parity feature, four quarters for a differentiated alternative. The intermediate window is the buying opportunity. The post-parity window is a margin compression story.
- Is this a one-off product release or a category shift?
- A category shift. The same primitive Geisinger reshapes here is showing up across at least two adjacent vendors' roadmaps. The framing differs; the underlying move on point-of-care workflow does not.
- What does this mean for incumbents whose the point-of-care workflow business depends on the old model?
- Either reprice or repackage. The incumbents who reprice within ninety days hold the renewal cohort. The ones who attempt to repackage without repricing lose the lower half of the install base within a year. Both outcomes are visible in prior category transitions.
The next ninety days will tell whether the cohort behavior holds across renewal cycles. We are bullish on the structural read, cautious on the speed of the competitive response, and watching the regulatory posture in one jurisdiction in particular. INTELAR will revisit this story in the next edition.